Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment

References

• El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: diagnosis, pathogenesis and treatment options. Nova Science Publishers, Inc; NY, USA: 2012
   Google Scholar
• Locke GR 3rd, Yawn BP, Wollan PC, et al. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Ther 2004;19:1025-31
   PubMedGoogle Scholar
• Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003;163:265-74
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• Thompson WG. A world view of IBS. In: Camilleri M, Spiller RC, editors. Irritable bowel syndrome. Saunders; Philadelphia and London: 2002. p. 17-26
   Google Scholar
• Quigley EM, Locke GR, Mueller-Lissner S, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther 2006;24:411-19
   PubMed Web of Science ®Google Scholar
• Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987;1:963-5
   PubMed Web of Science ®Google Scholar
• Norgaard M, Farkas DK, Pedersen L, et al. Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer 2011;104:1202-6
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne AM, et al. Racial differences in the impact of irritable bowel syndrome on health-related quality of life. J Clin Gastroenterol 2004;38:782-9
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Burnett CK, Cook EW 3rd, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41:2248-53
   PubMed Web of Science ®Google Scholar
• Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003;38:1031-8
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-50
   PubMed Web of Science ®Google Scholar
• Coffin B, Dapoigny M, Cloarec D, et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004;28:11-15
   PubMedGoogle Scholar
• Li FX, Patten SB, Hilsden RJ, Sutherland LR. Irritable bowel syndrome and health-related quality of life: a population-based study in Calgary, Alberta. Can J Gastroenterol 2003;17:259-63
   PubMedGoogle Scholar
• Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther 2004;19:1217-24
   PubMed Web of Science ®Google Scholar
• Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41
   PubMed Web of Science ®Google Scholar
• Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983;1(8325):632-4
   PubMedGoogle Scholar
• Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87. e1171-1173
   PubMed Web of Science ®Google Scholar
• Boivin M. Socioeconomic impact of irritable bowel syndrome in Canada. Can J Gastroenterol 2001;15(Suppl B):8B-11B
   PubMedGoogle Scholar
• Gaburri M, Bassotti G, Bacci G, et al. Functional gut disorders and health care seeking behavior in an Italian non-patient population. Recenti Prog Med 1989;80:241-4
   PubMedGoogle Scholar
• Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:671-80
   PubMed Web of Science ®Google Scholar
• Jafri W, Yakoob J, Jafri N, et al. Irritable bowel syndrome and health seeking behaviour in different communities of Pakistan. J Pak Med Assoc 2007;57:285-7
   PubMedGoogle Scholar
• Schlemper RJ, van der Werf SD, Vandenbroucke JP, et al. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol Suppl 1993;200:33-41
   PubMedGoogle Scholar
• Karaman N, Turkay C, Yonem O. Irritable bowel syndrome prevalence in city center of Sivas. Turk J Gastroenterol 2003;14:128-31
   PubMedGoogle Scholar
• Kwan AC, Hu WH, Chan YK, et al. Prevalence of irritable bowel syndrome in Hong Kong. J Gastroenterol Hepatol 2002;17:1180-6
   PubMed Web of Science ®Google Scholar
• Hoseini-Asl MK, Amra B. Prevalence of irritable bowel syndrome in Shahrekord, Iran. Indian J Gastroenterol 2003;22:215-16
   PubMedGoogle Scholar
• Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980;79:283-8
   PubMed Web of Science ®Google Scholar
• Kennedy TM, Jones RH, Hungin AP, et al. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998;43:770-4
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
   PubMed Web of Science ®Google Scholar
• Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-50
   PubMed Web of Science ®Google Scholar
• Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992;304:87-90
   PubMed Web of Science ®Google Scholar
• Bordie AK. Functional disorders of the colon. J Indian Med Assoc 1972;58:451-6
   PubMedGoogle Scholar
• O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995;50:M184-9
   PubMed Web of Science ®Google Scholar
• Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991;100:998-1005
   PubMed Web of Science ®Google Scholar
• Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004;54:495-502
   PubMed Web of Science ®Google Scholar
• Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009;11:265-9
   PubMedGoogle Scholar
• El-Salhy M, Gundersen D, Gilja OH, et al. Is irritable bowel syndrome an organic disorder? World J Gastroenterol 2014;2:384-400
   Google Scholar
• Longstreth GF, Hawkey CJ, Mayer EA, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001;15:959-64
   PubMed Web of Science ®Google Scholar
• Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190-2
   PubMed Web of Science ®Google Scholar
• Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008;20:46-50
   PubMed Web of Science ®Google Scholar
• Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-96
   PubMed Web of Science ®Google Scholar
• Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004;49:469-74
   PubMed Web of Science ®Google Scholar
• Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1788, 1789-94. quiz 1795
   Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Mol Med Rep 2013;7:1081-5
   PubMed Web of Science ®Google Scholar
• Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-72
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702
   PubMed Web of Science ®Google Scholar
• Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012;36:1009-31
   PubMed Web of Science ®Google Scholar
• Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig 2010;102:637-47
   PubMedGoogle Scholar
• Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig 2010;102:711-17
   PubMedGoogle Scholar
• Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4
   PubMed Web of Science ®Google Scholar
• Jellema P, van der Windt DA, Schellevis FG, van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009;30:695-706
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008;300:1793-805
   PubMed Web of Science ®Google Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999;45(Suppl 2):II1-5
   PubMedGoogle Scholar
• Lin OS. Colonoscopy in irritable bowel syndrome: whom are we reassuring? Gastrointest Endosc 2005;62:900-2
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. Aliment Pharmacol Ther 2003;17:651-4
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Lomholt-Beck B, Gundersen D. The prevalence of celiac disease in patients with irritable bowel syndrome. Mol Med Rep 2011;4:403-5
   PubMed Web of Science ®Google Scholar
• El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012;18:5151-63
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Halwe J, Lomholt-Beck B, Gundersen D. The prevalence of inflammatory bowel diseases, microscopic colitis, and colorectal cancer in patients with irritable bowel syndrome. Gastroenterology Insights 2011;3:7-10
   Google Scholar
• Tolliver BA, Herrera JL, DiPalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994;89:176-8
   PubMed Web of Science ®Google Scholar
• Camilleri M. Do the Symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? The con argument. Clin Gastroenterol Hepatol 2009;8:129
   PubMedGoogle Scholar
• Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007;25(3):323-32
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005;128:580-9
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T, Gundersen D, et al. Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report. BMC Res Notes 2013;6:391
   PubMedGoogle Scholar
• Spiller RC. Potential biomarkers. Gastroenterol Clin North Am 2011;40:121-39
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 2009;58:1571-5
   PubMed Web of Science ®Google Scholar
• Sjolund K, Sanden G, Hakanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983;85:1120-30
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Vaali K, Dizdar V, Hausken T. Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 2010;55:3508-13
   PubMed Web of Science ®Google Scholar
• Sandstrom O, el-Salhy M. Human rectal endocrine cells and aging. Mech Ageing Dev 1999;108:219-26
   PubMed Web of Science ®Google Scholar
• Sandstrom O, El-Salhy M. Ageing and endocrine cells of human duodenum. Mech Ageing Dev 1999;108:39-48
   PubMed Web of Science ®Google Scholar
• Sandström O. Age-related changes in the neuroendocrine system of the gut: a possible role in the pathogenesis of gastrointestinal disorders in the elderly. In: Umeå University Medical Dissertations, editors. Umeå; Umeå, Sweden: 1999. p. 1-46
   Google Scholar
• El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2010;45:1435-9
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Gundersen D, et al. Duodenal chromogranin A cell density as a biomarker for the diagnosis of irritable bowel syndrome World J Gastroenterol. 2014; In press
   Google Scholar
• El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept 2014;188:60-5
   PubMed Web of Science ®Google Scholar
• Wendelbo I, Mazzawi T, El-Salhy M. Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. Mol Med Rep 2014;9:180-4
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Wendelbo IH, Gundersen D. Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep 2013;7:1241-4
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T, Gundersen D, Hausken T. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep 2012;6:1223-5
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Lillebo E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med 2009;23:703-7
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Gundersen D, Hausken T. Endocrine cells in the gastric oxyntic mucosa of patients with irritable bowel syndrome. World J Gastrintest Endos 2014; In press
   Google Scholar
• El-Salhy M, Gundersen D, Ostgaard H, et al. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 2012;57:873-8
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG, Hausken T. Duodenal chromogranin A cell density as a biomarker for the diagnosis of irritable bowel syndrome. Regul Pept 2014; Submitted
   PubMedGoogle Scholar
• El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Gastric endocrine cells in the oxyntic mucosa of patients with irritable bowel syndrome. W J Gastrointest Endoscop 2014; In press
   PubMedGoogle Scholar
• El-Salhy M, Gilja OH, Hatlebakk JG, Hausken T. Gastric antral endocrine cells in patients with irritable bowel syndrome. Histol Histopathol 2014; Submitted
   Google Scholar
• El-Salhy M, Gilja OH, Hausken T. Chromogranin A cells in the stomach of patients with sporadic irritable bowel syndrome. Mol Med Rep 2014; In press
   Google Scholar
• Sjolund K, Ekman R, Wierup N. Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides 2010;31:1109-12
   PubMed Web of Science ®Google Scholar
• Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007;13:6041-7
   PubMed Web of Science ®Google Scholar
• Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2006;18:539-46
   PubMed Web of Science ®Google Scholar
• Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Wendelbo I, Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 2013;8:451-5
   PubMed Web of Science ®Google Scholar
• Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101
   PubMed Web of Science ®Google Scholar
• Dizdar V, Spiller R, Singh G, et al. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010;31:883-91
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-9
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003;98:1578-83
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23:1689-94
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11
   PubMed Web of Science ®Google Scholar
• Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection – an observation in a small case control study. Yonsei Med J 2010;51:45-51
   PubMed Web of Science ®Google Scholar
• Hotoleanu C, Popp R, Trifa AP, et al. Genetic determination of irritable bowel syndrome. World J Gastroenterol 2008;14:6636-40
   PubMedGoogle Scholar
• Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986;27:37-40
   PubMed Web of Science ®Google Scholar
• Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-12
   PubMed Web of Science ®Google Scholar
• Kalantar JS, Locke GR 3rd, Zinsmeister AR, et al. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003;52:1703-7
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004;49:1046-53
   PubMed Web of Science ®Google Scholar
• Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-17
   PubMed Web of Science ®Google Scholar
• Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804
   PubMed Web of Science ®Google Scholar
• Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 2007;25:1343-50
   PubMed Web of Science ®Google Scholar
• Wojczynski MK, North KE, Pedersen NL, Sullivan PF. Irritable bowel syndrome: a co-twin control analysis. Am J Gastroenterol 2007;102:2220-9
   PubMed Web of Science ®Google Scholar
• Bengtson MB, Ronning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006;55:1754-9
   PubMed Web of Science ®Google Scholar
• Mohammed I, Cherkas LF, Riley SA, et al. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005;100:1340-4
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 2007;133:1755-60
   PubMed Web of Science ®Google Scholar
• Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev 2008;22:1856-64
   PubMed Web of Science ®Google Scholar
• Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7
   PubMed Web of Science ®Google Scholar
• Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19:379-83
   PubMed Web of Science ®Google Scholar
• Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. Am J Anat 1974;141:537-61
   PubMedGoogle Scholar
• Le Douarin NM, Teillet MA. The migration of neural crest cells to the wall of the digestive tract in avian embryo. J Embryol Exp Morphol 1973;30:31-48
   PubMedGoogle Scholar
• Rawdon BB, Andrew A. Origin and differentiation of gut endocrine cells. Histol Histopathol 1993;8:567-80
   PubMed Web of Science ®Google Scholar
• Hoffman J, Kuhnert F, Davis CR, Kuo CJ. Wnts as essential growth factors for the adult small intestine and colon. Cell cycle (Georgetown, Tex.) 2004;3:554-7
   PubMed Web of Science ®Google Scholar
• Lee CS, Kaestner KH. Clinical endocrinology and metabolism. Development of gut endocrine cells. Best Pract Res Clin Endocrinol Metab 2004;18:453-62
   PubMedGoogle Scholar
• May CL, Kaestner KH. Gut endocrine cell development. Mol Cell Endocrinol 2010;323:70-5
   PubMed Web of Science ®Google Scholar
• Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 2011;92:219-31
   PubMed Web of Science ®Google Scholar
• Fishbein TM, Novitskiy G, Lough DM, et al. Rejection reversibly alters enteroendocrine cell renewal in the transplanted small intestine. Am J Transplant 2009;9:1620-8
   PubMed Web of Science ®Google Scholar
• Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 2006;355:270-80
   PubMed Web of Science ®Google Scholar
• Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome. Dig Liver Dis 2009;41:844-9
   PubMedGoogle Scholar
• Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-88
   PubMed Web of Science ®Google Scholar
• Spiller RC. Irritable bowel syndrome: bacteria and inflammation–clinical relevance now. Curr Treat Options Gastroenterol 2007;10:312-21
   PubMedGoogle Scholar
• Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42(Suppl 17):41-7
   PubMedGoogle Scholar
• Sarna SK. Lessons learnt from post-infectious IBS. Front Physiol 2011;2:49
   PubMedGoogle Scholar
• Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010;16:30-4
   PubMedGoogle Scholar
• Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol 2010;25:244-51
   PubMedGoogle Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome–a meta-analysis. Am J Gastroenterol 2006;101:1894-9. quiz 1942
   PubMed Web of Science ®Google Scholar
• Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007;45(Suppl 2):S115-19
   PubMedGoogle Scholar
• Wheatcroft J, Wakelin D, Smith A, et al. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005;17:863-70
   PubMed Web of Science ®Google Scholar
• Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 2010;161:19-27
   PubMed Web of Science ®Google Scholar
• Ghia JE, Li N, Wang H, et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009;137:1649-60
   PubMed Web of Science ®Google Scholar
• Yang GB, Lackner AA. Proximity between 5-HT secreting enteroendocrine cells and lymphocytes in the gut mucosa of rhesus macaques (Macaca mulatta) is suggestive of a role for enterochromaffin cell 5-HT in mucosal immunity. J Neuroimmunol 2004;146:46-9
   PubMedGoogle Scholar
• Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97-105
   PubMedGoogle Scholar
• Wouters MM, Boeckxstaens GE. Neuroimmune mechanisms in functional bowel disorders. Neth J Med 2011;69:55-61
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Lilbo E, Reinemo A, et al. Effects of a health program comprising reassurance, diet management, probiotic administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. Gastroenterology Insights 2010;2:21-6
   Google Scholar
• Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984;2:1232-4
   PubMed Web of Science ®Google Scholar
• Palsson OS, Turner MJ, Johnson DA, et al. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002;47:2605-14
   PubMed Web of Science ®Google Scholar
• Lindfors P, Unge P, Arvidsson P, et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012;107:276-85
   PubMed Web of Science ®Google Scholar
• Wilson S, Maddison T, Roberts L, et al. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:769-80
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Svensen R, Hatlebakk JG, et al. Chronic constipation and treatment options (Review). Mol Med Rep 2014;9:3-8
   PubMedGoogle Scholar
• Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol 2014;48(1):21-8
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-67
   PubMed Web of Science ®Google Scholar
• Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999-e541
   PubMed Web of Science ®Google Scholar
• Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32:1113-23
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e1117
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology 2013;145(6):1334-46. e1311
   PubMed Web of Science ®Google Scholar
• Rao SS, Quigley EM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   Google Scholar
• Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22(3):312-e384
   PubMed Web of Science ®Google Scholar
• Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86(19-20):760-5
   PubMed Web of Science ®Google Scholar
• Sood R, Ford AC. Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Ther Adv Chronic Dis 2013;4(6):268-76
   PubMedGoogle Scholar
• Carballo F. Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity. Rev Esp Enferm Dig 2013;105(6):345-54
   PubMedGoogle Scholar